Roivant Sciences Ltd.
IMVT-1402
Graves’ disease
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for IMVT-1402 in Graves’ disease are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“Recent Phase 2 proof-of-concept data highlighted FcRn blockade as a potentially disease-modifying approach in Graves’ disease. Topline data from the potentially registrational studies of IMVT-1402 in Graves’ disease are expected in calendar”